%0 Journal Article %T A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease %A Hank Safferstein %A Jason D. Lickliter %A Julie Pribyl %A Kelsie Mozzoni %A Lon S. Schneider %A Michael Grundman %A Michelle Higgin %A Nicholas J. Izzo %A Robert Guttendorf %A Roger Morgan %A Steven DeKosky %J Archive of "Alzheimer's & Dementia : Translational Research & Clinical Interventions". %D 2019 %R 10.1016/j.trci.2018.11.001 %X Elayta (CT1812) is a novel allosteric antagonist of the sigma-2 receptor complex that prevents and displaces binding of A¦Â oligomers to neurons. By stopping a key initiating event in Alzheimer's disease, this first-in¨Cclass drug candidate mitigates downstream synaptotoxicity and restores cognitive function in aged transgenic mouse models of Alzheimer's disease %K CT1812 %K Alzheimer's disease (AD) %K Amyloid beta (A¦Â) %K Safety %K Pharmacokinetics %K Clinical trial %K Therapy %K Single ascending dose (SAD) %K Multiple ascending dose (MAD) %K Cerebrospinal fluid (CSF) %U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352291/